A few years back MannKind was criticized about using overseas clinical trial sites and more specifically Russian sites. Now the overseas sites are applying pressure on the company to gain approval so their own population can have access to this innovative therapy.

Come on FDA, approve the drug and let the world decide how much or how little they want to use it.